Although both clinical and biological markers are associated with response to EGFR inhibitors, attempts to improve predictive accuracy using single-gene biomarkers such as EGFR mutation/amplification status, or KRAS gain-of-function mutations have been marginally successful, depending on the tumour type. Here, EGFR is linked to neoplasm.